High complete response rate seen with novel CAR-T for myelomaDecember 7, 2019Multiple MyelomaImmuno-oncologyOncologyRare Diseases
Patient-reported outcomes support first-line pembrolizumab for NSCLCDecember 6, 2019Lung CancerImmuno-oncologyOncology
Bilateral mastectomy reduces second breast cancer risk, but not deathsDecember 6, 2019Breast CancerOncologyWomen's Health
Sequential CRT, immunotherapy nets high PFS in node-positive cervical cancerDecember 2, 2019OncologyImmuno-oncology
ASH preview: Key themes include tackling CAR T obstacles, sickle cell advances, VTENovember 26, 2019Multiple MyelomaImmuno-oncologyOncology
Combo elicits lasting responses in metastatic melanomaNovember 25, 2019MelanomaImmuno-oncologyOncologyDermatology
Atezolizumab/bevacizumab may offer benefit to patients with RCCNovember 25, 2019Genitourinary CancerImmuno-oncologyOncology
Early lenalidomide may delay progression of smoldering myelomaNovember 19, 2019Multiple MyelomaOncology
Support for medical marijuana transcends political affiliationNovember 15, 2019OncologyPainAddiction Medicine
Nivolumab-ipilimumab combo has ‘robust’ clinical benefit in sorafenib-treated HCC patientsNovember 14, 2019Oncology
Combo produces disappointing PFS, promising OS in metastatic colorectal cancerNovember 13, 2019Immuno-oncologyOncology
